Table 1.
Summary of the pharmacokinetic parameters for oral and intraperitoneal route of magnolol and mag@Uio-66(Zr).
| Test Compound | Parameters | |||||
|---|---|---|---|---|---|---|
| AUC0–720 (µg/mL min) | AUC0–∞ (µg/mL min) | Tmax (min) | Cmax (µg/mL) | T1/2 (min) | Abs T1/2 (min) | |
| Magnolol PO | 823.3 ± 139.10 | 903.97 ± 140.09 | 55.77 ± 4.17 | 2.57 ± 0.26 | 100 ± 20.40 | 23.26 ± 3.16 |
| Mag@Uio-66(Zr) PO | 1823 ± 167.31 * | 2099.95 ± 148.48 * | 196.97 ± 17.38 * | 3.77 ± 0.33 * | 206.21 ± 27.95 * | 118.92 ± 6.22 * |
| Magnolol IP | 2582.67 ± 150.48 | 4016.90 ± 535.62 | 64.06 ± 6.88 | 5.10 ± 0.65 | 460.88 ± 37.41 | 17.14 ± 3.63 |
| Mag@Uio-66(Zr) IP | 2312.67 ± 253.76 | 3831.72 ± 451.57 | 114.27 ± 7.09 ** | 5.65 ± 2.41 | 606.35 ± 114.37 | 33.26 ± 4.09 ** |
n = 3; Data presented as mean ± S.E.M. * significant difference between oral route at 95% confidence interval; ** significant difference between intraperitoneal route at 95% confidence interval; PO—oral route; IP—intraperitoneal route; AUC0–720—area under the curve from 0 to 720 min; Cmax—maximal plasma concentration; Tmax—maximal time reaching the maximal plasma concentration; T1/2—elimination half-life; Abs T1/2—absorption half-life.